Core Viewpoint - Norska's stock price has shown a positive trend with an 8.48% increase year-to-date, reflecting investor confidence in the company's growth potential in the clinical trial services sector [2]. Company Overview - Norska (Beijing) Pharmaceutical Technology Co., Ltd. was established on August 22, 2008, and went public on August 2, 2022. The company is located in Haidian District, Beijing [2]. - The company's main business includes clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [2]. - Revenue composition: Clinical trial operation services (39.25%), clinical trial site management services (34.10%), data management and statistical analysis services (13.30%), biological sample testing services (8.45%), clinical pharmacology services (3.74%), and clinical trial consulting services (1.16%) [2]. Financial Performance - For the first half of 2025, Norska achieved operating revenue of 380 million yuan, a year-on-year increase of 0.18%, and a net profit attributable to shareholders of 61.12 million yuan, up 4.45% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 49.50 million yuan [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 10,400, with an average of 5,486 circulating shares per person, a decrease of 1.97% from the previous period [2]. - New significant shareholders include Hong Kong Central Clearing Limited and two funds from Zhonggeng, indicating growing institutional interest [3].

9月23日，诺思格跌5.08%，截至发稿，报52.52元/股，成交8287.77万元，换手率2.69%，总市值50.72亿 元。诺思格股价已经连续4天下跌，区间累计跌幅4.6%。 资料显示，诺思格(北京)医药科技股份有限公司位于北京市海淀区车公庄西路19号华通大厦B座北塔11 层，成立日期2008年8月22日，上市日期2022年8月2日，公司主营业务涉及临床试验运营服务、临床试 验现场管理服务、生物样本检测服务、数据管理与统计分析服务、临床试验咨询服务、临床药理学服务 等。主营业务收入构成为：临床试验运营服务39.25%，临床试验现场管理服务34.10%，数据管理与统 计分析服务13.30%，生物样本检测服务8.45%，临床药理学服务3.74%，临床试验咨询服务1.16%。 从基金十大重仓股角度 数据显示，东财基金旗下1只基金重仓诺思格。东财远见成长混合发起式A（018088）二季度持有股数 1.24万股，占基金净值比例为4.85%，位居第五大重仓股。根据测算，今日浮亏损失约3.48万元。连续4 天下跌期间浮亏损失3.31万元。 东财远见成长混合发起式A（018088）成立日期2023年4月11日，最新规模9 ...

Group 1 - Norsg's stock price increased by 5.35% on September 10, reaching 61.80 CNY per share, with a trading volume of 263 million CNY and a turnover rate of 7.73%, resulting in a total market capitalization of 5.969 billion CNY [1] - The stock has risen for eight consecutive days, with a cumulative increase of 13.95% during this period [1] - Norsg (Beijing) Pharmaceutical Technology Co., Ltd. specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [1] Group 2 - The East Finance Growth Mixed Fund A (018088) holds 12,400 shares of Norsg, accounting for 4.85% of the fund's net value, making it the fifth-largest holding [2] - The fund has generated a floating profit of approximately 38,900 CNY today and 89,000 CNY during the eight-day rising period [2] - The fund was established on April 11, 2023, with a latest scale of 9.6956 million CNY and has achieved a year-to-date return of 47.97% [2]

从基金十大重仓股角度 数据显示，西藏东财基金旗下1只基金重仓诺思格。东财远见成长混合发起式A（018088）二季度持有 股数1.24万股，占基金净值比例为4.85%，位居第五大重仓股。根据测算，今日浮盈赚取约3.61万元。 连续4天上涨期间浮盈赚取4.48万元。 东财远见成长混合发起式A（018088）成立日期2023年4月11日，最新规模969.56万。今年以来收益 47.41%，同类排名760/8180；近一年收益84.81%，同类排名595/7978；成立以来亏损1.81%。 东财远见成长混合发起式A（018088）基金经理为孙辰阳。 9月4日，诺思格涨5.28%，截至发稿，报58.00元/股，成交6604.47万元，换手率2.03%，总市值56.02亿 元。诺思格股价已经连续4天上涨，区间累计涨幅7.01%。 截至发稿，孙辰阳累计任职时间2年148天，现任基金资产总规模2439.93万元，任职期间最佳基金回报 39.2%， 任职期间最差基金回报-28.98%。 资料显示，诺思格(北京)医药科技股份有限公司位于北京市海淀区车公庄西路19号华通大厦B座北塔11 层，成立日期2008年8月22日，上市日期2 ...

Core Insights - On August 29, Norscare's stock rose by 2.93% with a trading volume of 166 million yuan [1] - The company reported a financing buy-in of 15.92 million yuan and a financing repayment of 17.69 million yuan, resulting in a net financing outflow of 1.77 million yuan [1] - As of August 29, the total financing and securities lending balance for Norscare was 84.92 million yuan, which is 2.80% of its market capitalization, indicating a high level of financing balance compared to the past year [1] Company Overview - Norscare (Beijing) Pharmaceutical Technology Co., Ltd. was established on August 22, 2008, and went public on August 2, 2022 [2] - The company specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [2] - The revenue composition includes: clinical trial operation services (43.01%), clinical trial site management services (27.52%), data management and statistical analysis services (13.53%), biological sample testing services (8.54%), clinical pharmacology services (4.33%), and clinical trial consulting services (3.08%) [2] Financial Performance - For the first half of 2025, Norscare achieved a revenue of 380 million yuan, representing a year-on-year growth of 0.18% [2] - The net profit attributable to the parent company was 61.12 million yuan, reflecting a year-on-year increase of 4.45% [2] - Cumulative cash dividends since the A-share listing amount to 49.50 million yuan [3] Shareholder Structure - As of June 30, 2025, the number of shareholders for Norscare was 10,400, an increase of 2.06% from the previous period [2] - The average number of circulating shares per shareholder was 5,486, a decrease of 1.97% from the previous period [2] - New institutional shareholders include Hong Kong Central Clearing Limited and two funds from Zhonggeng, which entered the top ten circulating shareholders [3]

Core Viewpoint - The company Norse Group (Beijing) Pharmaceutical Technology Co., Ltd. has shown stable financial performance with slight growth in revenue and net profit, while also experiencing significant trading activity in its stock. Group 1: Financial Performance - For the period from January to June 2025, Norse Group achieved operating revenue of 380 million yuan, representing a year-on-year growth of 0.18% [2] - The net profit attributable to the parent company was 61.12 million yuan, reflecting a year-on-year increase of 4.45% [2] - Cumulative cash dividends since the company's A-share listing amounted to 49.50 million yuan [3] Group 2: Business Operations - The company's main business segments include clinical trial operation services (43.01%), clinical trial site management services (27.52%), data management and statistical analysis services (13.53%), biological sample testing services (8.54%), clinical pharmacology services (4.33%), and clinical trial consulting services (3.08%) [2] - As of June 30, 2025, the number of shareholders increased to 10,400, up by 2.06% from the previous period, while the average circulating shares per person decreased by 1.97% to 5,486 shares [2] Group 3: Stock Trading Activity - On August 28, Norse Group's stock price fell by 0.39%, with a trading volume of 149 million yuan [1] - The financing buy-in amount for Norse Group on the same day was 19.42 million yuan, with a net buy of 5.95 million yuan after 13.47 million yuan in financing repayments [1] - The total financing and securities lending balance reached 86.69 million yuan, accounting for 2.94% of the circulating market value, indicating a high level compared to the past year [1]

Company Overview - Norscog (Beijing) Pharmaceutical Technology Co., Ltd. specializes in providing integrated drug clinical research and development services for global pharmaceutical companies and research institutions [1] - The main products include clinical trial operation services, clinical trial site management services, data management and statistical analysis services, biological sample testing services, clinical trial consulting services, and clinical pharmacology services [1] Financial Performance - For Q1 2025, the company reported revenue of 173 million yuan, a year-on-year decrease of 2.53% [1] - The net profit for the same period was 26.07 million yuan, reflecting a year-on-year increase of 13.12% [1] - The sales gross margin stood at 36.53% [1] Market Position - As of August 20, Norscog's stock closed at 54.8 yuan, down 2.73%, with a rolling price-to-earnings (PE) ratio of 36.95 times [1] - The total market capitalization is 5.293 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical services sector is 49.21 times, with a median of 65.65 times, placing Norscog at 23rd in the industry ranking [1][2] Institutional Holdings - As of Q1 2025, only one institution holds shares in Norscog, which is a fund with a total holding of 12,400 shares valued at 0.01 million yuan [1]

Company Overview - Norsg achieved a closing price of 56.3 yuan on August 6, with a decline of 2.54%, resulting in a rolling price-to-earnings (PE) ratio of 37.96 times and a total market capitalization of 5.438 billion yuan [1] - The company specializes in providing integrated drug clinical research and development services for global pharmaceutical enterprises and research institutions, including clinical trial operation services, site management services, data management and statistical analysis services, biological sample testing services, clinical trial consulting services, and clinical pharmacology services [1] Financial Performance - In the first quarter of 2025, Norsg reported an operating income of 173 million yuan, a year-on-year decrease of 2.53%, while net profit was 26.0737 million yuan, reflecting a year-on-year increase of 13.12%, with a gross profit margin of 36.53% [1] Industry Comparison - The average PE ratio for the medical services industry is 47.47 times, with a median of 58.53 times, placing Norsg at the 23rd position within the industry [1] - The static PE ratio for Norsg is 38.78 times, with a price-to-book ratio of 2.92 [2] - Other companies in the industry include WuXi AppTec with a PE of 19.52 times, and Kanglong Chemical with a PE of 28.02 times, indicating a competitive landscape [2] Capital Flow - On August 6, Norsg experienced a net outflow of 9.3516 million yuan in principal funds, with a total outflow of 55.8066 million yuan over the past five days, indicating a trend of capital outflow [1]

Group 1 - The core viewpoint of the articles highlights that Norsg has a closing price of 57.77 yuan, with a PE ratio of 38.95 times and a total market value of 5.579 billion yuan [1] - The company operates in the medical services industry, which has an average PE ratio of 47.93 times and a median of 59.03 times, placing Norsg at the 23rd position in the industry ranking [1][2] - Norsg's main business involves providing comprehensive drug clinical research and development services to global pharmaceutical companies and research institutions, including clinical trial operation services and data management [1] Group 2 - In the latest quarterly report for Q1 2025, Norsg reported an operating income of 173 million yuan, a year-on-year decrease of 2.53%, while net profit was 26.0737 million yuan, reflecting a year-on-year increase of 13.12% [1] - The company's gross profit margin stands at 36.53% [1] - On August 5, 2023, Norsg experienced a net outflow of 7.64 million yuan in principal funds, with a total outflow of 59.9384 million yuan over the past five days [1]

Company Overview - Norsg has a closing price of 56.0 yuan, down 2.27%, with a rolling PE ratio of 37.76 times and a total market value of 5.409 billion yuan [1] - The company operates in the medical services industry, which has an average PE ratio of 47.90 times and a median of 59.27 times, placing Norsg at the 23rd position in the industry ranking [1] Financial Performance - For Q1 2025, Norsg reported revenue of 173 million yuan, a year-on-year decrease of 2.53%, and a net profit of 26.0737 million yuan, a year-on-year increase of 13.12%, with a gross profit margin of 36.53% [1] - As of Q1 2025, there is one institutional holder of Norsg, which is a fund holding a total of 12,400 shares valued at 0.01 million yuan [1] Industry Comparison - The industry average PE ratio is 47.90 times, while the industry median is 59.27 times, indicating that Norsg's PE ratio is below both metrics [2] - Norsg's market value is 5.409 billion yuan, which is significantly lower than other companies in the industry, such as WuXi AppTec with a market value of 267.116 billion yuan [2]